433 related articles for article (PubMed ID: 36866389)
1. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
[TBL] [Abstract][Full Text] [Related]
2. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
Loomba R; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Harrison SA; Lawitz EJ; Gunn N; Imajo K; Ravendhran N; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Abdelmalek MF
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):102-112.e9. PubMed ID: 37088457
[TBL] [Abstract][Full Text] [Related]
3. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
Abdelmalek MF; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Lawitz EJ; Harrison SA; Jacobson IM; Imajo K; Gunn N; Halegoua-DeMarzio D; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Loomba R
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):113-123.e9. PubMed ID: 37088458
[TBL] [Abstract][Full Text] [Related]
4. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
[TBL] [Abstract][Full Text] [Related]
6. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
Luo Y; Decato BE; Charles ED; Shevell DE; McNaney C; Shipkova P; Apfel A; Tirucherai GS; Sanyal AJ
JHEP Rep; 2022 Jan; 4(1):100392. PubMed ID: 34977519
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
9. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
10. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
[TBL] [Abstract][Full Text] [Related]
11. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
[TBL] [Abstract][Full Text] [Related]
12. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
Sanyal AJ; Ling L; Beuers U; DePaoli AM; Lieu HD; Harrison SA; Hirschfield GM
JHEP Rep; 2021 Jun; 3(3):100255. PubMed ID: 33898959
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
Vali Y; Lee J; Boursier J; Petta S; Wonders K; Tiniakos D; Bedossa P; Geier A; Francque S; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison SA; Chen Y; Cobbold JF; Pavlides M; Holleboom AG; Yki-Jarvinen H; Crespo J; Karsdal M; Ostroff R; Zafarmand MH; Torstenson R; Duffin K; Yunis C; Brass C; Ekstedt M; Aithal GP; Schattenberg JM; Bugianesi E; Romero-Gomez M; Ratziu V; Anstee QM; Bossuyt PM;
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):714-725. PubMed ID: 36958367
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
Joy TR; McKenzie CA; Tirona RG; Summers K; Seney S; Chakrabarti S; Malhotra N; Beaton MD
World J Gastroenterol; 2017 Jan; 23(1):141-150. PubMed ID: 28104990
[TBL] [Abstract][Full Text] [Related]
16. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
[TBL] [Abstract][Full Text] [Related]
17. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
[TBL] [Abstract][Full Text] [Related]
18. The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis.
Mi YJ; Zhang Z; Jin SL; Yan HM; Yang XM; Zhao J; Liu RX; Wu Y
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1052-1059. PubMed ID: 38375710
[TBL] [Abstract][Full Text] [Related]
19. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
Amernia B; Moosavy SH; Banookh F; Zoghi G
BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
